Genmab — September 2019
-
Mcjean havde et pragtfuldt skriv om de amerikanske banker og emissionen.
-
the importance of selling in 1st line.... "In the “real world” only 61% of patients receive a second line therapy and only 38% actually receive a third line" https://twitter.com/IMFjimMYELOMA/status/1172477308260818944
-
spot on indeed https://twitter.com/MM_Hub/status/1172472467471970304
-
nogen, der har opfanget noget på twitter?
-
Vi har næsten 300 besøgende lige nu i chatten.
-
En del fra Holland.
-
Ingen ved noget åbenbart.
-
-
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous,...
GlobeNewswire News Room (www.globenewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind